Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
Rhea-AI Summary
Revolution Medicines (Nasdaq: RVMD) has announced a forthcoming investor webcast to provide clinical updates on their RAS(ON) inhibitor portfolio. The event, focused on their targeted therapies for RAS-addicted cancers, is scheduled for December 2, 2024, at 8:00 a.m. Eastern Time. The webcast will be accessible online, with a replay available on the company's website's Events & Presentations page for at least 14 days after the live event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, RVMD declined 1.25%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide clinical updates from its RAS(ON) inhibitor portfolio.
The webcast will take place at 8:00 a.m. Eastern Time on Monday, December 2, 2024. To access the webcast, click here. An archived replay will be available on the “Events & Presentations” page of the Revolution Medicines website at https://ir.revmed.com/events-and-presentations for at least 14 days following the live event.
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in addition to RAS companion inhibitors RMC-4630 and RMC-5552.
FAQ
When is Revolution Medicines (RVMD) hosting its RAS(ON) inhibitor clinical update webcast?
How long will the replay of RVMD's December 2024 clinical update webcast be available?
What is the focus of Revolution Medicines' (RVMD) December 2024 webcast?
Where can investors access RVMD's December 2024 clinical update webcast?
